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Argentina
Multi-target drugs have raised considerable interest in the last decade owing to their
advantages in the treatment of complex diseases and health conditions linked to
drug resistance issues. Prospective drug repositioning to treat comorbid conditions is
an additional, overlooked application of multi-target ligands. While medicinal chemists
usually rely on some version of the lock and key paradigm to design novel therapeutics,
modern pharmacology recognizes that the mid- and long-term effects of a given drug
on a biological system may depend not only on the specific ligand-target recognition
events but also on the influence of the repeated administration of a drug on the cell gene
signature. The design of multi-target agents usually imposes challenging restrictions on
the topology or flexibility of the candidate drugs, which are briefly discussed in the present
article. Finally, computational strategies to approach the identification of novel multi-target
agents are overviewed.
Keywords: multi-target agents, lock and key paradigm, gene profile, drug resistance, drug repositioning, drug
design, designed multiple ligands
Introduction
Multi-target drugs (or multi-functional drugs or network therapeutics) have attracted considerable
attention in the last decade, as potential therapeutic solutions to diseases of complex etiology (Talevi
et al., 2012; Koerberle and Werz, 2014; Zheng et al., 2014) and health conditions linked to drug-
resistance issues (Talevi and Bruno-Blanch, 2013; Li et al., 2014). According to the “one drug, one
target” paradigm, highly potent and specific (single-target) treatments would be better tolerated due
to absence of off-target side-effects. However, poor correlation between in vitro drug effects and
in vivo efficacy is often found with target-driven approximations (Kell, 2013; Margineanu, 2014).
While target-first strategies might prove useful to approach single gene disorders, disease is often
a multifactorial condition involving a combination of constitutive and/or environmental factors.
Owing to compensatory mechanisms and redundant functions, biological systems are resilient to
single-point perturbations (Hopkins, 2008). Under such perspective, disease often results from the
breakdown of robust physiological systems due to multiple genetic and/or environmental factors,
leading to the establishment of robust disease conditions (Yildrim et al., 2007). Thus, complex
disorders are more likely to be healed or alleviated though simultaneous modulation of multiple
targets.
Though this strategy has only been purposely applied in the last 10 to 15 years, many of
the previously known therapeutic agents are in fact multi-target ligands (Yildrim et al., 2007),
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FIGURE 1 | Extrapolation of the classic lock and key analogy to multi-target agents.
which is especially true for those drugs that were discovered by
serendipity, phenotypic screening or traditional medicine. Note
that in all these cases, the knowledge on the pharmacological effect
precedes the knowledge of the mode of action. Aspirin itself has
been shown to act through a diversity of molecular mechanisms
besides cyclooxygenase inhibition (Koerberle and Werz, 2014).
Some therapeutic categories, e.g., mood disorder medications,
are particularly abundant on classical examples of multi-target
drugs (Roth et al., 2004). So actually, multi-target drugs have
long been known and effectively used in the clinical practice but
have majorly been found serendipitously or through phenotypic
screening. What are the possibilities and limitations of tailored
multi-target drugs?
Revisiting and Squeezing the Classical
Lock and Key Paradigm
Medicinal chemists usually resort to the traditional lock and
key model to describe the interaction between a ligand and its
molecular target (or an updated version of this paradigm that
contemplates the ligand and target flexibility, such as the hand-
in-glove analogy). The general idea is that the ligand (the key)
and the target (the lock) should have complementary features to
efficiently interact and trigger some biological response (open
the lock). Frequently, different ligands can elicit a qualitatively
similar response at a certain target. For different keys to activate
the same lock alike they must share some common, essential
arrangement of features (the blade of the key), whichwill be termed
the pharmacophore (from the Greek, what carries the medicine).
The remaining part of the key (the bow) may be indeed important,
but less subject to structural restrictions (Figure 1).
A multi-target ligand might be conceived as a skeleton or
master key capable of unlocking several locks. While selective
non-selectivity might be of benefit, promiscuity (non-selective
non-selectivity) might in contrast raise severe safety concerns
and should be avoided. Why may a non-promiscuous ligand
activate different targets? There are many possible answers to this
question. First, it is frequent for a given ligand to act on several
isoforms of the same protein. For instance, xilocaine (lidocaine)
can produce anesthetic, antiarrhythmic and anticonvulsant effects
by blocking the peripheral nervous system, heart and central
nervous system sodium channels (Catterall, 2000). Alternatively,
different members of a given biochemical pathway might share,
to some extent, ligand specificity due to co-evolution. Finally,
a ligand might display affinity to two or more unrelated
targets by combining different pharmacophores in the same
molecule (Morphy et al., 2004). Frequently, such combination of
pharmacophores leads to molecules that are either enthalpically
or entropically unfavorable, which conspires against the design of
multi-target drugs, as will be later discussed in the correspondent
section. This is metaphorically represented in Figure 1, through
the awkward design of key number 3.
The contribution of biotechnology, however, has made very
clear that the lock and key analogy can fall short to explain
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the effects of a drug on a biological system, particularly when
medium- and long-term drug exposure (multiple-dose regimens)
is required. After sustained exposure to a chemical agent the
gene signature of a cell varies: some genes are upregulated while
others are downregulated (e.g., owing to activation of nuclear
receptors, compensatory mechanisms, etc.). Whereas in the past
attention was directed to the direct interactions between the
drug and its molecular target/s, now it is known that a more
holistic perspective is needed to fully characterize the action of
a drug on a biological system. For example, it has been reported
that chronic administration of valproic acid and carbamazepine
downregulates cytosolic phospholipase A2 and/or cyclooxygenase
(with the consequent reduction of proinflammatory cytokines;
Bosetti et al., 2003; Gherlardoni et al., 2004), an effect that may
be involved in the effectiveness of these agents in epilepsy and
bipolar disorder. The need for such holistic view is unequivocally
expressed in the Connectivity Map, a publicly available resource
meant to connect disease and small molecules through gene-
profiles (Qu and Rajpal, 2012). The Connectivity Map stores gene
expression profiles derived from the treatment of human cells
cultured with a large number of drugs; when a disease signature
is used as a query, it is expected that those drugs related to the
disease by opposite expression changes (inverse similarity) will be
potential treatments.
Possible Applications of Multi-Target
Ligands
Threemain applications ofmulti-target agents in a therapeutic can
be envisioned.
Complex Disorders
Complex disorders are multi-factorial health conditions triggered
by a number of intrinsic and/or environmental factors acting
together on an organism. Among them we may mention mood
disorders, neurodegenerative diseases, chronic inflammation or
cancer. Despite the advances on the comprehension of the
biological basis of these conditions and the huge investments
made by the pharmaceutical sector, pharmaceutical solutions
remain elusive. Although in some cases such disorders can be or
are approached through combined therapies, multi-target ligands
would present clear advantages, among them more predictive
pharmacokinetics, better patient compliance, and reduced risk
of drug interactions. There are several reviews available covering
the potential of the multi-target approach in cancer (Petrelli and
Giordano, 2008; Petrelli andValabrega, 2009), Alzheimer’s disease
(Bajda et al., 2011; Dias and Viegas, 2014; Zheng et al., 2014),
Parkinson’s disease (Youdim et al., 2014), inflammation (Hwang
et al., 2013), depression and other psychiatric disorders (Wong
et al., 2008; Milan, 2014).
Drug Resistance
Simultaneously impacting different targets could also be
advantageous to approach individuals expressing intrinsic
or induced variability in drug response due to modifications
in key disease-relevant biological pathways and activation of
compensatory mechanisms (Zimmermann et al., 2007; Xie
et al., 2012). Apart from the obvious applications in the field
of antimicrobial chemotherapy (it is less probable to develop
resistance linked to single-point mutations against multi-target
than single-target agents) this strategy could also be pertinent to
treat non-infectious conditions characterized by high incidence
of the drug resistance phenomena, e.g., epilepsy (Bianchi et al.,
2009; Margineanu, 2014). One third of the epileptic patients
suffer from refractory epilepsy. One of the prevalent hypotheses
to explain refractory epilepsy cases proposes that at least part of
the non-responsive patients might express variations inmolecular
targets of antiepileptic drugs (Talevi and Bruno-Blanch, 2013).
Isobolographic studies in animal models and clinical experience
suggest that combination of drugs with different mechanisms
tends to be beneficial (Kwan and Brodie, 2006; Kaminski et al.,
2009; Lee and Dworetzky, 2010; Brodie et al., 2011). On the
other hand, while there exists consensus regarding the utility of
single-target drugs for the treatment of some specific epilepsy
types or syndromes, broad spectrum antiepileptic drugs such as
valproic acid are among the most used antiepileptic agents and
might be valuable in those cases where, at the onset of epilepsy,
diagnosis of the specific syndrome is elusive (Bourgeois, 2007;
Lagae, 2009; Löscher et al., 2013; Margineanu, 2014).
Prospective Drug Repositioning
Drug repositioning (i.e., finding a second or further medical
use for already known therapeutics, including approved,
discontinued, shelved, and experimental drugs) has attracted
enormous interest within the academic and pharmaceutical
sectors during the last 10 years (Ashburn and Thor, 2004; Novac,
2013). Most of the successful drug repositioning cases have been
found by serendipity or through exploitation of the original
action mechanism of a drug for new indications (on target
repositioning). Multi-target agents are natural candidates for
more innovative, off-target drug repositioning. Computational
approaches to drug repositioning have so far focused on what
we will call retrospective drug repositioning: screening known
drugs collections/libraries to find novel indications for already
known therapeutic agents. Prospective drug repositioning, in
contrast, would explore drug repositioning possibilities much
earlier in the drug discovery process. While some pharmaceutical
companies now consider exploring repositioning alternatives for
drugs in the pipeline, the approach could be taken much further,
by designing multi-purpose drugs to treat different conditions;
prominently, frequently co-morbid disorders (e.g., diabetes and
cardiac disease; anxiety and peptic ulcer disease, epilepsy, and
depression) or, alternatively, underlying pathologies plus disease
symptoms. The case of amiodarone and related compounds and
Chagas disease can be illustrative. Chagas disease is a tropical
parasitic disease historically endemic to Latin America. The late
phase of the disease is characterized by life-threatening heart
disorder in around one third of the patients. Amiodarone is a
class III antiarrhythmic agent that shares many characteristics
of other electrophysiological anti-arrhythmic drugs, including
inhibition of sodium and potassium channels and L-type calcium
channels. Interestingly, some studies showed that patients with
chagasic cardiomyopathy treated with amiodarone had a more
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rapid recovery when compared with other patients treated with
class I and class IV antiarrhythmics. This fact suggested that
other mode of action could be in play. It was later demonstrated
that amiodarone was able to act directly on the parasite
survival, affecting the growth of Trypanosoma cruzi extracellular
epimastigotes and T. cruzi amastigotes (that is, amiodarone
could act on the underlying pathology). The mechanism of
action of the drug was elucidated, showing that this drug directly
disrupts the intracellular calcium regulation of the parasite
(Benaim et al., 2006). Similar results were later observed with
dronedarone (Benaim et al., 2012). Still, this example is another
case of retrospective drug repositioning, since the new medical
use emerged from clinical observations. A future challenge is to
define whether this kind of indication expansion oriented to the
treatment of co-morbid conditions could be anticipated through
rational approaches at early stages of the drug development
process, thus helping to provide evidence on possible advantages
of new treatments compared to the existent ones, and additional
criteria to decide which drug candidates should be prioritized to
clinical trials and to conveniently choose the clinical endpoints
of the trial that will be used to test superiority or non-superiority
of the treatments under comparison. Computational network-
based approximations could prove valuable to unveil hidden
connections between diseases and assist these types of initiatives.
Some Considerations Related to the
Design and Screening of Multi-Target
Agents
Development of tailored multi-target agents with affinity to
unrelated or weakly related drug targets relies mainly in
two approaches (Morphy et al., 2004; Ma et al., 2010): the
methodical combination of pharmacophores from selective,
single-target ligands (a fragment-based approach) and; the
screening of compound collections by simultaneous application
of multiple computational models (or a single, multi-tasking
computational model) to identify compounds with a suitable
combination of activities. In the first approximation, the distinct
pharmacophores are joined together by a cleavable or stable
linker or, alternatively, they are overlapped by taking advantage of
structural commonalities (Morphy et al., 2004). The use of linkers
often leads to compounds with unfavorable biopharmaceutic
or pharmacokinetic profile (e.g., compounds that violate more
than two of the Lipinski’s rules). Although the use of cleavable
linkers might be advantageous, it also limits some of the merits
of the multi-target approach in comparison with combination
therapies (simplified pharmacokinetics, reduced chance of drug
interactions). Moreover, the fragment-based approach could
lead to poor ligand efficiency metrics (Hopkins et al., 2014),
which refer to the binding efficiency per atom. It might
be speculated that, since only a part of the molecule can
interact with each of the proposed targets, the other part can
become an obstacle for the binding event, reducing the binding
efficiency because of enthalpic and/or entropic reasons, which
is represented through the awkward topology of key number
3 (Figure 1). Therefore, the overlapping or merging approach
(searching partially or highly integrated pharmacophores in a
small molecule) seems more attractive from a biopharmaceutical
viewpoint. Including some degree of flexibility in the molecule
may help the common and non-common pharmacophoric
features to accommodate to the correspondent binding sites of
the different intended targets; however, the degree of flexibility
should be carefully tuned so that an excess of flexibility does
not conspire against the binding affinity (owing to unfavorable
entropic loss associated to the binding event) or the bioavailability
of the drug (it should be remembered that many druglikeness
rules limit the number of flexible bonds in the molecule). An
illustrative example of some of these principles is provided
by the recent research from Jayaraman et al. (2013). These
authors applied the fragment-based approach in the design
of phytochemical-antibiotic conjugates conceived as multivalent
inhibitors of Pseudomonas aeruginosa DNA gyrase subunit B
(GyrB)/topoisomerase IV subunit B, dihydrofolate reductase
(DHFR) and dihydropteroate synthase (DHPS). Departing from
previously identified pharmacophores for inhibitors of E. coli
GyrB andDHFR, the authors derived a common pharmacophoric
model for multi-inhibition of such enzymes. Remarkably, they
decided on using simple phenols (gallic acid and protocatechuic
acid, simpler structural analogs of the bivalent natural product
epigallocatechin gallate) conjugated through a non-cleavable
linker to sulfamethoxazole and sulfadiazine (which inhibit
DHPS; Figure 2). The decision of using simple phytochemicals
as departure points resulted in four drug-like compounds
with acceptable computed biopharmaceutical properties, which
was checked through different drug-likeness rules (Lipinski
and Veber rules) and by predicting the solubility and the
percentage of absorption for the designed drug candidates. Two
of the candidates displayed no violation of the rule of five
and Veber rules, while the remaining two showed only one
violation of Lipinski rules and marginal violation of Veber
rules.
Regarding the screening approximation, one should bear in
mind that the hit rate in the screening campaign is expected to
be lower than the ones obtained when looking for single-target
drug candidates (Talevi et al., 2012): each model used in the
in silico screening process functions as a structural restriction
that filters out all the molecules that do not gather the model
requisites; thus, the more models used, the less probable it
is to find chemical compounds accomplishing all the models
structural constraints. For example,Nair et al. (2013) have recently
performed a virtual screening campaign to identify multi-target
inhibitors of DAP-kinases (a family of pro-apoptotic proteins also
involve in autophagy, which are proposed as a promising target for
therapeutic intervention of brain ischemia and neurodegenerative
diseases). AmongDAP-kinases, DRP1 has been reported to be the
upstream protein of all the DAP-kinases as it is involved in the
activation of other members of the family. However, modulation
of DRP1 is not enough to attenuate the cell death pathways
activated by DAP-kinases, owing to the existence of alternative
activating sources. Searching for multi-target agents, the authors
have explored a combined database of 391 known ligands of one
of three members of the DAP-kinases family: DAPk1, DRP1, and
ZIPk. This library was compiled from the Protein Data Bank
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FIGURE 2 | Multi-target antibiotic phyto-drug conjugates designed by Jayaraman et al. (2013).
and ChEMBL, and it was sequentially screened through three
pharmacophore hypothesis of DAPk1, DRP1, and ZIPk, in that
order. Screening using the first hypothesis (DAPk1) resulted in
196 hits. Further, screening of these hits by DRP1 pharmacophore
resulted in 56 hits, which contained pharmacophore features of
both DAPk1 and DRP1 ligands. The 56 ligand hits were then
screened by the ZIPk pharmacophore, retrieving only four ligands
gathering the pharmacophoric features of all three DAP-kinases.
The limited number of hits obtained when using sequential
in silico filters/models to select multi-target agents might be
compensated by the huge, ever expanding available chemical
universe. Multitasking QSAR approximations (Zanni et al., 2014;
Speck-Planche and Cordeiro, 2015) could prove as a valuable tool
to implement this strategy.
Target Selection
So far the advantages and challenges posed by the multi-target
approach have been discussed. A critical question remains,
however, to be made: if we are to design multi-target agents, how
shall we choose our molecular targets? Obviously, a drug target
needs to have the potential to be disease modifying. Secondly,
if we are fighting against an infection or a deregulated cell (e.g.,
in cancer) the drug must display some degree of selectivity, e.g.,
the drug target must be exclusively or preferentially expressed in
the infectious agent or in the cancerous cell, targeted proteins
in a pathogen should not have homologous proteins in the
host or homologous proteins in the host should be sufficiently
different from those in the pathogen, etc. Furthermore, the
Medicinal Chemistry community has long accepted that not all
the proteins are equally “druggable,” i.e., likely to be moderated by
small molecules. A number of approaches to assess druggability
have been proposed in the specialized literature, from “guilt
by association” approximations (a protein is predicted to be
druggable if it belongs to a protein family for which at least one
member of the family is targeted by a drug) to methods based on
binding site prediction, among others (Keller et al., 2006; Cheng
et al., 2007). But still the previous are just general considerations
valid for both single- and multi-target approximations. When
aiming at multiple targets, the choice of the targets and the
pursued type of inhibition depend on several factors, among
them the nature of the disease (infectious disease? complex
disorder?) and/or the possible mechanisms of drug resistance
(adaptive mechanisms? target amplification or mutation?). A
relevant issue that deserves attention is whether it is preferable
to directly block the selected targets or to modulate them (e.g.,
through weak partial inhibitions). Under our modern paradigm,
built on a systems biology perspective, it is understood that,
in general, we are not targeting isolated proteins but pathways
instead. We might target different signaling pathways (parallel
targeting), which may be valuable to block escape routes, adaptive
resistance mechanism and compensatory homeostatic responses;
alternatively, vertical targeting (attacking the same pathway
at different nodes) might prove useful against other types of
resistance (e.g., target mutations; Shahbazian et al., 2012). When
trying to kill pathogens or malignant cells, attacking hubs (highly
connected nodes in a biochemical network) might be the strategy
of choice; on the other hand, if the treatment objective is to
restore a perturbed network to a healthy state, using low affinity
multi-target ligands to modulate multiple non-crucial nodes
neighboring key nodes ligands might be advantageous in order
to avoid sever side-effects (that might be otherwise expected
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if blocking a key node with a crucial physiological function;
Csernely et al., 2013). Metabolic control analysis constitutes a
useful frame to evaluate the importance and relative contribution
of individual metabolic steps in the overall functioning of a
particular system and, subsequently, to identify optimal targets
(Hornberg et al., 2007).
Conclusion
Multi-target agents are a promising strategy to face complex,
multifactor disorders and drug resistance issues. Additionally,
they can prove valuable in prospective drug repositioning oriented
to the treatment of comorbid conditions or both the underlying
pathology and its symptoms, an overlooked application to the
moment. Compared to combination therapies, they present
several advantages, includingmore predictable pharmacokinetics,
lower probabilities of drug interactions and higher patient
compliance.
We have highlighted some difficulties related to the search
of tailored multi-target drugs (e.g., enthalpic and entropic
considerations and potential bioavailability issues, limited
number of hits when sequentially screening a virtual library).
Besides the classical key and lock paradigm to approach the
multi-target strategy, the effect of the drug on cell gene signatures
should also be considered, especially when looking for middle-
and long-term treatments, which is often the case for complex
disorders. Finally, network analysis might provide clues to help
target selection, which is highly dependent on the nature of the
treated disorder and the known mechanisms of resistance.
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